Dr. Monika Srivastava, MD

Dr. Srivastava practices at Selectskinmd in Vero Beach, Florida.

Dr. Srivastava's NPI, 1437117058, was assigned on May 3, 2006. Dr. Srivastava graduated from The Johns Hopkins University School of Medicine in 2002. Dr. Srivastava holds Florida license ME101443.

Dr. Srivastava's primary practice is Selectskinmd, at 1600 36th St Suite B Suite B, Vero Beach, FL 32960-4875. The practice phone is (772) 567-1164.

Dr. Srivastava's primary practice is Selectskinmd in Vero Beach, Florida. The medical group on file is Select Skin MD.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Srivastava practices. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Srivastava's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Srivastava is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Srivastava's licenses on file in 5 states: Florida, New Jersey, New York, Massachusetts and Virginia.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses and facial skin infection among the conditions Dr. Srivastava treats.

CMS data shows 25,339 Medicare services from Dr. Srivastava across 42 procedure codes in 2024, for 2,153 Medicare patients. Medicare paid $3,529,492 for them. Every service was in an office.

CMS counts 2,153 Medicare patients who saw Dr. Srivastava in 2024. The largest group is 75 to 84, with 1,107 patients. 75% of them have high cholesterol, and 67% have high blood pressure. Their average risk score is 1.01, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Srivastava's median patient age at 78, with 56% women.

In 2024, Dr. Srivastava wrote 2,526 Medicare Part D claims for 1,297 patients. 100% of them were for generic drugs. CMS names the drug for 2,435 of them, across 19 drugs with 11 or more claims each, at $26,993 in total drug cost. In 2023, CMS named 2,758 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Srivastava for performance year 2024, reported individually. Dr. Srivastava accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 3,286 procedures of removal of skin lesions by Dr. Srivastava, more than 99% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 5 papers to Dr. Srivastava in 2006. Dr. Srivastava has published most often in Arch Dermatol. Dr. Srivastava's most frequent co-authors are Grant James Anhalt, MD and Carlos H. Nousari, MD.

CMS Open Payments shows 6 general payments to Dr. Srivastava from 3 drug and device companies from 2017 to 2024. Food and beverage make up the largest share, 58% of the total. Galderma Laboratories, L.P. paid the most, $93.

Dmand AI lists 2 awards for Dr. Srivastava.

Dr. Srivastava graduated from The Johns Hopkins University School of Medicine in 2002. Dr. Srivastava is a member of AAD and ASDS.

Dr. Srivastava is in network with 15 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.